目的 比较瑞舒伐他汀与阿托伐他汀治疗冠心病心绞痛的临床效果。方法 选取2015年1月-2016年3月就诊于咸阳市第一人民医院心血管内科的冠心病心绞痛患者200名，随机分为对照组和治疗组，每组各100例。对照组患者口服阿托伐他汀钙片，20 mg/次，1次/d。治疗组口服瑞舒伐他汀钙片，10 mg/次，1次/d。两组均连续治疗6周。观察两组的临床疗效，比较两组治疗前后低密度胆固醇（LDL-C）、总胆固醇（TC）、三酰甘油（TG）、心绞痛发作频率及每次心绞痛发作持续时间的变化情况。结果 治疗后，对照组和治疗组的总有效率分别为73%、91%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者LDL-C、TC水平均显著降低，对照组TG水平显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组LDL-C、TC显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组心绞痛发作频率和心绞痛持续时间均明显减少，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组心绞痛持续时间明显短于对照组，两组比较差异具有统计学意义（P<0.05）。结论 瑞舒伐他汀治疗冠心病心绞痛具有较好的临床疗效，能显著降低LDL-C、TC水平，缩短心绞痛持续时间，具有一定的临床推广应用价值。

Objective To compare the clinical effect of rosuvastatin and atorvastatin in treatment of coronary heart disease angina pectoris. Methods Patients (200 cases) with coronary heart disease angina pectoris in the First People's Hospital of Xianyang City from January 2015 to March 2016 were randomly divided into control (100 cases) and treatment (100 cases) groups. Patients in the control group were po administered with Atorvastatin Calcium Tablets, 20 mg/time, once daily. Patients in the treatment group were po administered with Rosuvastatin Calcium Tablets, 10 mg/time, once daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the changes of LDL-C, TC, TG, angina attack frequency and angina attack duration in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment group were 73% and 91%, and there were differences between two groups (P<0.05). After treatment, LDL-C and TC in two groups were significantly decreased, and TG in the control group was significantly decreased, and there were differences in the same group (P<0.05). After treatment, LDL-C and TC in the treatment group were lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, angina attack frequency and angina attack duration in two groups were significantly decreased, and there were differences in the same group (P<0.05). After treatment, angina attack frequency and angina attack duration in the treatment group were shorter than those in the control group, and there were differences between two groups (P<0.05). Conclusions Rosuvastatin has significant clinical effect in treatment of coronary heart disease angina pectoris, can significantly reduce LDL-C and TC levels, and can shorten the duration of angina pectoris, which has a certain clinical application value.